Today: 30 April 2026
Browse Category

XETRA:SIEGN.DE 11 January 2026 - 8 February 2026

Siemens stock price rises after Copenhagen driverless train deal as earnings week looms

Siemens stock price rises after Copenhagen driverless train deal as earnings week looms

Siemens shares rose 2.45% to 250.50 euros Friday after its Mobility unit and a Stadler-led group secured a 3 billion euro contract to supply automated trains for Copenhagen. The deal covers 226 trainsets, with service running through 2040. Siemens will report first-quarter results and hold its annual meeting on Feb. 12, with a proposed 5.35 euro dividend per share on the agenda.
8 February 2026
··

Stock Market Today

  • Standard Chartered Shares Surge on Record Q1: A FTSE 100 Banking Opportunity?
    April 30, 2026, 8:53 AM EDT. Standard Chartered (LSE: STAN) shares jumped 4% following a record first quarter, contrasting with losses seen in Lloyds Banking Group's stock despite better-than-expected results. CEO Bill Winters highlighted strong growth in Wealth Solutions and Global Banking, with full-year 2026 guidance maintained at 5%-7% operating income growth. The bank posted a 9% rise in operating profit to $5.9 billion and a 17% increase in pre-tax profit to $2.5 billion, despite $296 million in impairment charges linked to Middle East conflicts. Shares trade at a price-to-earnings ratio of 11, with a modest 2.6% dividend yield expected in 2026. Investors weigh the risks of emerging market exposure against steady profits and disciplined risk management.

Latest article

QUALCOMM Incorporated (QCOM) Stock Jumps as AI Data-Center Bet Offsets Weak Forecast

QUALCOMM Incorporated (QCOM) Stock Jumps as AI Data-Center Bet Offsets Weak Forecast

30 April 2026
Qualcomm shares rose 10.3% premarket Thursday after CEO Cristiano Amon said the smartphone market had bottomed and highlighted progress in data-center chips. Fiscal Q2 revenue fell 3% to $10.6 billion, with handset revenue down 13% but automotive up 38%. The Q3 forecast missed Wall Street estimates. Qualcomm expects chip sales to Chinese handset makers to recover after Q3.
Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

30 April 2026
Eli Lilly raised its 2026 revenue forecast by $2 billion after first-quarter sales jumped 56% to $19.8 billion, driven by Mounjaro and Zepbound, which brought in $12.8 billion. Adjusted earnings reached $8.55 per share. The company cited strong demand but noted lower realized prices and competition from Novo Nordisk remain risks. Foundayo, Lilly’s new oral GLP-1 pill, launched in April but was not included in the quarter’s results.
Go toTop